Skip to main content

Survival and Extent of Breast Surgery in Patients with Complete Response After Neoadjuvant Therapy: A Retrospective Analysis from the EUSOMA Database

In brief

Recurrence was 5.2% after breast-conserving surgery, 12.5% after mastectomy

In this retrospective cohort of 467 women with a complete response to preoperative therapy, recurrence was less common after breast-conserving surgery than mastectomy over a median 5.6 years. Mastectomy patients more often had multifocal or advanced disease, and surgery type did not affect overall survival; the findings support breast conservation but cannot prove it lowers recurrence.

Journal
Cancers (Q1)
Published
3 November 2026
Study design
Retrospective cohort
Evidence level
Level 3, Low (CEBM 3b)
Authors
Federica Martorana, Damiano Gentile, Mariano Tomatis, Antonio Ponti, Lorenza Marotti, Cynthia Aristei, et al.
PMID
43026857
DOI
10.3390/cancers18213536

Why clinicians should know about it

  • Picked for Surgical Oncology (paper of the day, 17 November 2026): Directly compares breast conservation versus mastectomy after pCR

Abstract

BACKGROUND: Optimal management of breast cancer (BC) patients with pathological complete response (pCR) after neoadjuvant therapy (NAT) remains debated. We performed a retrospective analysis to evaluate whether the extent of surgery influences survival outcomes in this patient population. METHODS: Using the EUSOMA database, we retrospectively collected data of women with pCR after NAT, excluding those with BRCA1/2 mutations. The cohort was stratified by surgery type, i.e., breast-conserving surgery (BCS) or mastectomy. Relapse-free survival (RFS) and overall survival (OS) were compared using Cox regression. RESULTS: Of 467 patients, 327 (70.0%) underwent BCS and 140 (30.0%) underwent mastectomy. Women treated with mastectomy were more likely to have multifocal tumors and advanced disease. After a median follow-up of 5.6 years, 7.3% of patients experienced BC recurrence. Axillary nodal involvement (cN+) and mastectomy were independently associated with recurrence, occurring in 11.4% of cN+ compared to 3.7% of cN0 patients (HR 3.02; 95% CI: 1.40-6.51; p = 0.005) and in 12.5% of mastectomy vs. 5.2% of BCS patients (HR 2.08; 95% CI: 1.05-4.11; p 0.035). cN+ patients also showed significantly higher mortality rates (9.4% vs. 1.6% of cN0; HR 6.16; 95%CI: 2.09-18.17; p = 0.001). However, surgery type did not impact OS. CONCLUSIONS: In this cohort of BC patients with pCR after NAT, BCS was not associated with a higher risk of recurrence compared with mastectomy. Baseline nodal involvement independently predicted recurrence and mortality; however, the type of surgery did not impact OS. These findings support BCS as a safe treatment option for this patient population.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.